CYCC - Cyclacel Pharmaceuticals jumps on preclinical data for blood cancer treatment fadraciclib

Shares of biopharmaceutical company Cyclacel Pharmaceuticals (NASDAQ:CYCC) have added 13.2% in premarket trading on Tuesday after announcing publication of preclinical data confirming that its CDK2/9 inhibitor fadraciclib suppresses the protein MCL1 and synergizes with oral therapy venetoclax in the treatment of chronic lymphocytic leukemia. Publication announced in the journal Leukemia. Results from the study confirmed that fadraciclib reduced levels of the short-lived anti-apoptotic protein MCL1 and induced apoptosis in primary chronic lymphocytic leukemia cells. Fadraciclib was also shown to combine synergistically with venetoclax, the only FDA-approved apoptosis enabling, leukemia treatment. The data supports the rationale for pursuing clinical development of fadraciclib, either alone or in combination with a BCL2 antagonist, for the treatment of chronic lymphocytic leukemia.

For further details see:

Cyclacel Pharmaceuticals jumps on preclinical data for blood cancer treatment fadraciclib